BioAge Labs, Inc (BIOA) - Total Assets
Based on the latest financial reports, BioAge Labs, Inc (BIOA) holds total assets worth $396.93 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioAge Labs, Inc - Total Assets Trend (2013–2025)
This chart illustrates how BioAge Labs, Inc's total assets have evolved over time, based on quarterly financial data. Also see BioAge Labs, Inc (BIOA) total market value for the company's overall valuation and market capitalisation.
BioAge Labs, Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
BioAge Labs, Inc's total assets of $396.93 Million consist of 97.3% current assets and 2.8% non-current assets. Review BIOA total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.1% |
| Accounts Receivable | $769.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how BioAge Labs, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of BioAge Labs, Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioAge Labs, Inc's current assets represent 97.3% of total assets in 2025, an increase from 83.2% in 2013.
- Cash Position: Cash and equivalents constituted 64.1% of total assets in 2025, down from 73.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
BioAge Labs, Inc Competitors by Total Assets
Key competitors of BioAge Labs, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
BioAge Labs, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.19 | 13.21 | 0.37 |
| Quick Ratio | 17.19 | 13.21 | 0.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $311.10 Million | $278.86 Million | $-18.84 Million |
BioAge Labs, Inc - Advanced Valuation Insights
This section examines the relationship between BioAge Labs, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -17.7% |
| Total Assets | $294.89 Million |
| Market Capitalization | $371.31 Million USD |
Valuation Analysis
Above Book Valuation: The market values BioAge Labs, Inc's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: BioAge Labs, Inc's assets decreased by 17.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioAge Labs, Inc (2013–2025)
The table below shows the annual total assets of BioAge Labs, Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $294.89 Million | -17.68% |
| 2024-12-31 | $358.23 Million | +1281.86% |
| 2023-12-31 | $25.92 Million | -8.81% |
| 2022-12-31 | $28.43 Million | -59.10% |
| 2017-12-31 | $69.51 Million | -56.91% |
| 2016-12-31 | $161.33 Million | +12.75% |
| 2015-12-31 | $143.09 Million | -6.14% |
| 2014-12-31 | $152.44 Million | +33.63% |
| 2013-12-31 | $114.08 Million | -- |
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more